942590-05-8

Basic information

• Product Name: 1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester
• Synonyms: tert-Butyl 5-bromo-1H-benzo[d]imidazole-1-carboxylate;5-Bromobenzimidazole-1-carboxylic acid tert-butyl ester;1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester;5-BroMo-benzoiMidazole-1-carboxylic acid tert-butyl ester;tert-Butyl 5-bromo-1H-benzimidazole-1-carboxylate
• CAS NO: 942590-05-8
• Molecular Formula: C₁₂H₁₃BrN₂O₂
• Molecular Weight: 297.14782
• Mol File: 942590-05-8.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester(942590-05-8)
• EPA Substance Registry System: 1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester(942590-05-8)

Safety Data

• Hazardous Substances Data: 942590-05-8(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole-1-carboxylic acid, 5-bromo-, 1,1-dimethylethyl ester is a chemical compound with the molecular formula C11H14BrN3O2. It is a ester derivative of 5-bromo-1H-benzimidazole-1-carboxylic acid, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drug molecules. 1H-BenziMidazole-1-carboxylicacid,5-broMo-,1,1-diMethylethylester has been studied for its potential anti-cancer and anti-inflammatory properties, with research focusing on its ability to inhibit certain enzymes and pathways involved in these diseases. It is also used as a reagent in chemical and biochemical research.

InChI:InChI=1S/C12H13BrN2O2/c1-12(2,3)17-11(16)15-7-14-9-6-8(13)4-5-10(9)15/h4-7H,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 4887-88-1 5-bromo-1H-benzo[d]imidazole 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Downstream Products

• 942590-06-9 1,1-dimethylethyl 6-(4-{4-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-5-[(methyloxy)carbonyl]-2-thienyl}phenyl)-1H-benzimidazole-1-carboxylate 
• 1021918-86-4 1,1-dimethylethyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole-1-carboxylate 
• 1008359-49-6 1,1-dimethylethyl 5-(3-formylphenyl)-1H-benzimidazole-1-carboxylate 
• 1021916-56-2 6-(1H-benzo[d]imidazol-5-yl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one; 
• 1426095-41-1 4-(1H-benzimidazol-5-yl)-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-(phenylmethyl)benzamide 
• 1426095-32-0 4-(1H-benzimidazol-5-yl)-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-(1-methylethyl)benzamide 

Relevant articles and documents

Aminomethylation of Aryl Bromides by Nickel-Catalyzed Electrochemical Redox Neutral Cross Coupling

We develop an electrochemical nickel-catalyzed aminomethylation of aryl bromides under mild conditions. The convergent paired electrolysis makes full use of anode and cathode processes, free of a terminal oxidant, a sacrificial anode, a metal reductant, and a prefunctionalized radical precursor. In addition, this method exhibits wide functional group tolerance (63 examples), including some sensitive substituents and aromatic heterocycles. This redox neutral cross coupling provides a more environmentally friendly and synthetic practical protocol for forging C(sp2)–C(sp3) bonds.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

ANTIMICROBIAL 4-OXOQUINOLIZINES

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful again